Denosumab-induced hypocalcemia may be more common than expected in osteoporotic men and women, according to real world data. An Israeli study of more than 2,000 community-living adults with osteoporosis treated with 60 mg denosumab every six months found 7.4% developed hypocalcemia (<8.5mg/dL). This rate is significantly higher than that seen in clinical trials (0.05-1.7 mg/dL). ...
Known risk of hypocalcemia with denosumab may have been underestimated
By Mardi Chapman
6 Apr 2020